ADRIATIC试验:局限期SCLC同步放化疗后度伐利尤单抗巩固治疗的患者报告结局
ADRIATIC III期试验首次 interim 分析显示,局限期SCLC同步放化疗后无进展患者接受度伐利尤单抗巩固治疗较安慰剂显著改善总生存和无进展生存。本次报告患者报告结局,度伐利尤单抗组与安慰剂组各关键量表评分变化小且无临床意义,除肩臂痛恶化时间延长和胸痛改善率更高外,两组恶化时间和改善率大多相似。结论认为度伐利尤单抗巩固治疗未损害患者整体健康状况/生活质量、功能或症状。
要点
- 度伐利尤单抗组与安慰剂组预设关键量表评分变化均小,未达临床意义阈值(≥10分)。
- 肩臂痛至恶化时间度伐利尤单抗组更长(中位25.7 vs 9.1个月;HR 0.70,95%CI 0.51-0.94)。
- 胸痛改善率度伐利尤单抗组更高(OR 2.28,95%CI 1.08-4.95)。
核心结论
- 局限期SCLC同步放化疗后度伐利尤单抗巩固治疗未损害患者整体健康状况/生活质量、功能或症状,支持其作为新标准治疗。
研究设计与样本
- III期ADRIATIC试验的患者报告结局分析,度伐利尤单抗组264例、安慰剂组266例,每4周给药至多24个月。
- 使用EORTC QLQ-C30和QLQ-LC13量表评估,分析至24个月评分变化、至恶化时间和改善率,未进行α控制。
主要发现
- 两组预设关键量表从基线至24个月的平均评分变化均小且无临床意义。
- 除肩臂痛外,两组至恶化时间无差异;肩臂痛中位至恶化时间度伐利尤单抗组25.7个月 vs 安慰剂组9.1个月(HR 0.70,95%CI 0.51-0.94)。
- 大多数量表两组改善率相似,胸痛改善率度伐利尤单抗组更高(OR 2.28,95%CI 1.08-4.95)。
关键数值与推荐
- 评分变化≥10分视为有临床意义的恶化或改善。
- 肩臂痛至恶化时间:度伐利尤单抗组中位25.7个月 vs 安慰剂组9.1个月,HR 0.70(95%CI 0.51-0.94)。
- 胸痛改善率:度伐利尤单抗组 vs 安慰剂组 OR 2.28(95%CI 1.08-4.95)。
临床怎么用
- 度伐利尤单抗巩固治疗不增加整体生活质量或症状负担,可与患者沟通其安全性。
- 治疗期间可关注肩臂痛,但该症状恶化时间在度伐利尤单抗组反而更长。
- 胸痛改善率更高可作为支持度伐利尤单抗治疗的额外获益信息。
局限性
- 分析未进行α控制,统计推断需谨慎解读。
- 度伐利尤单抗-替美木单抗组在此次分析时仍处于盲态,未纳入报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In the first interim analysis of the phase 3 ADRIATIC trial, consolidation durvalumab significantly improved overall survival and progression-free survival (primary end points) versus placebo in patients with limited-stage SCLC without disease progression after concurrent chemoradiotherapy. We report the patient-reported outcomes. METHODS: Patients received durvalumab, durvalumab-tremelimumab, or placebo every 4 weeks for up to 24 months. Patient-reported global health status/quality of life (QoL), functioning, and symptoms, assessed using the European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30-item and QoL Questionnaire-Lung Cancer 13-item (secondary end points), are reported for durvalumab and placebo only; the durvalumab-tremelimumab arm remained blinded at this analysis. Change from baseline (for prespecified key scales), time to deterioration (TTD), and improvement rates (all scales) were evaluated. A score change of more than or equal to 10 from baseline was considered a clinically meaningful deterioration or improvement. Analyses were not alpha controlled. RESULTS: In both arms (durvalumab, n = 264; placebo, n = 266), mean score changes in prespecified key scales from baseline up to 24 months were small and not clinically meaningful. There were no between-arm differences in TTD except for arm or shoulder pain (longer with durvalumab versus placebo [median TTD: 25.7 versus 9.1 mo; hazard ratio: 0.70 (95% confidence interval: 0.51-0.94)]) and similar improvement rates between arms for most scales; a higher improvement rate for chest pain was observed with durvalumab versus placebo (odds ratio: 2.28 [95% confidence interval: 1.08-4.95]). CONCLUSIONS: Consolidation durvalumab after concurrent chemoradiotherapy did not compromise patients' global health status/QoL, functioning, or symptoms versus placebo, further supporting this treatment regimen as the new standard of care for limited-stage SCLC.
引用
- Novello S, Spigel DR, Fang J, et al. Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial. J Thorac Oncol. 2026. PMID: 41621752. doi:10.1016/j.jtho.2026.103564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。